Signal of harm in morphine use in adults with acute pulmonary oedema: A rapid systematic review
DOI:
https://doi.org/10.7196/SAMJ.2023.v113i8.348Keywords:
Essential Medicines, Review, cardiopulmonary diseaseAbstract
Background. Heart failure affects nearly 65 million people globally, resulting in recurrent hospital admissions and substantial healthcare expenditure. The use of morphine in the management of acute pulmonary oedema remains controversial, with conflicting guidance and significant variation in practice. Synthesised evidence is needed to inform standard treatment guidelines and clinical practice.
Objective. To determine whether morphine should be used in the treatment of acute pulmonary oedema (APE) in adults.
Methods. A rapid review of systematic reviews of randomised controlled trials or observational studies, and then randomised controlled trials, was conducted searching three electronic databases (PubMed, Embase, Cochrane Library) and one clinical trial registry on 12 February 2022. We used a prespecified protocol following Cochrane rapid review methods and aligned to the National Standard Treatment Guidelines and Essential Medicines List methodology. We first considered relevant high-quality systematic reviews of randomised controlled trials or observational studies, then (if required) randomised controlled trials to inform time-sensitive or urgent evidence requests, clinical practice, policy, or standard treatment guidelines.
Results. We identified four systematic reviews of observational studies. The two most relevant, up-to-date, and highest-quality reviews were used to inform evidence for critical outcomes. Morphine may increase in-hospital mortality (odds ratio (OR) 1.78; 95% confidence interval (CI) 1.01 - 3.13; low certainty of evidence; six observational studies, n=151 735 participants), resulting in 15 more per 1 000 hospital deaths, ranging from 0 to 40 more hospital deaths. Morphine may result in a large increase in invasive mechanical ventilation (OR 2.72; 95% CI 1.09 - 6.80; low certainty of evidence; four observational studies, n=167 847 participants), resulting in 45 more per 1 000 ventilations, ranging from 2 more to 136 more. Adverse events and hospital length of stay were not measured across reviews or trials.
Conclusion. Based on the most recent, relevant and best-available quality evidence, morphine use in adults with APE may increase in-hospital and all-cause mortality and may result in a large increase in the need for invasive mechanical ventilation compared to not using morphine. Recommending against the use of morphine in pulmonary oedema may improve patient outcomes. Disinvesting in morphine for this indication may result in cost savings, noting the possible accrued benefits of fewer patients requiring invasive ventilation and management of morphine-related side-effects.
References
Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail
;22(8):1342-1356. https://doi.org/10.1002/ejhf.1858
Gil V, Domínguez-Rodríguez A, Masip J, Peacock WF, Miró Ò. Morphine use in the treatment of acute
cardiogenic pulmonary edema and its effects on patient outcome: A systematic review. Curr Heart Fail
Rep 2019;16(4):81-88. https://doi.org/10.1007/s11897-019-00427-0
Bleumink G, Knetsch A, Sturkenboom M, et al. Quantifying the heart failure epidemic: Prevalence,
incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur Heart J
;25(18):1614-1619. https://doi.org/10.1016/j.ehj.2004.06.038
Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93(9):1137-1146. https://doi.
org/10.1136/hrt.2003.025270
Kraus S, Ogunbanjo G, Sliwa K, Ntusi NAB. Heart failure in sub-Saharan Africa: A clinical approach.
S Afr Med J 2015;106(1):23. https://doi.org/10.7196/samj.2016.v106i1.10325
McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of
acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and
Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with
the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33(14):1787-1847. superscript 2
Gao D, David C, Rosa MM, Costa J, Pinto FJ, Caldeira D. The risk of mortality associated with opioid
use in patients with acute heart failure: Systematic review and meta-analysis. J Cardiovasc Pharmacol
;77(2):123-129. https://doi.org/10.1097/fjc.0000000000000954
Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized
for heart failure in the United States: Rationale, design, and preliminary observations from the first
,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J
;149(2):209-216. https://doi.org/10.1016/j.ahj.2004.08.005
Masip J, Peacock WF, Price S, et al. Indications and practical approach to non-invasive ventilation in
acute heart failure. Eur Heart J 2018;39(1):17-25. https://doi.org/10.1093/eurheartj/ehx580
Sosnowski MA. Lack of effect of opiates in the treatment of acute cardiogenic pulmonary oedema.
Emerg Med Australasia 2008;20(5):384-390. https://doi.org/10.1111/j.1742-6723.2008.01113.x
Allison RC. Initial treatment of pulmonary edema: A physiological approach. Am J Med Sci
;302(6):385-391. https://doi.org/10.1097/00000441-199112000-00013
Agewall S. Morphine in acute heart failure. J Thorac Dis 2017;9(7):1851-1854. https://doi.org/10.21037/
jtd.2017.06.129
Vatner SF, Marsh JD, Swain JA. Effects of morphine on coronary and left ventricular dynamics in
conscious dogs. J Clin Invest 1975;55(2):207-217. https://doi.org/10.1172/JCI107923
Lin Y, Chen Y, Yuan J, et al. Intravenous morphine use in acute heart failure increases adverse outcomes:
A meta-analysis. Rev Cardiovasc Med 2021;22(3):865. https://doi.org/10.31083/j.rcm2203092
Peacock WF, Hollander JE, Diercks DB, Lopatin M, Fonarow G, Emerman CL. Morphine and
outcomes in acute decompensated heart failure: An ADHERE analysis. Emerg Med J 2008;25(4):205-
https://doi.org/10.1136/emj.2007.050419
Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological
therapy for heart failure: An update of the 2013 ACCF/AHA Guideline for the Management of Heart
Failure: A report of the American College of Cardiology/American Heart Association Task Force
on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2016;134(13).
https://doi.org/10.1161/cir.0000000000000435
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of
acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic
heart failure of the European Society of Cardiology (ESC). Developed with the special contribution
of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37(27):2129-2200. https://doi.
org/10.1093/eurheartj/ehw128
Hitzeroth J, Mpe M, Klug E, et al. 2020 Heart Failure Society of South Africa perspective on the 2016
European Society of Cardiology Chronic Heart Failure Guidelines. S Afr Med J 2020;110(9b):935-951.
https://doi.org/10.7196/SAMJ.2020.v110i8.14681
Purvey M, Allen G. Managing acute pulmonary oedema. Aust Prescr 2017;40(2):59-63. https://doi.
org/10.18773/austprescr.2017.012
National Department of Health, South Africa. Hospital Level (Adults) Standard Treatment Guidelines
and Essential Medicines List. 2nd ed. https://knowledgehub.health.gov.za/elibrary/hospital-leveladults-standard-treatment-guidelines-and-essential-medicines-list-2nd (accessed 20 June 2023).
Gray A, Suleman F, Pharasi B. South Africa’s national drug policy: 20 years and still going? S Afr Health
Rev 2017;2017(1):49-58. https://doi.org/10.10520/EJC-c80c69129
National Department of Health, South Africa. National Drug Policy for South Africa Pretoria: NDoH,
https://www.gov.za/documents/national-drugs-policy (accessed 22 June 2023).
World Health Organization. Essential medicines, health product policy and standards, medicines
selection, IP and affordability. WHO model list of essential medicines, Geneva: WHO, 2019. https://
www.who.int/publications-detail-redirect/WHOMVPEMPIAU2019.06 (accessed 22 June 2023).
Leong TD, McGee SM, Gray AL, et al. Essential medicine selection during the COVID-19 pandemic:
Enabling access in uncharted territory. S Afr Med J 2020;110(11):1077. https://doi.org/10.7196/
samj.2020.v110i11.15271
South Africa GRADE Network. The Centre for Evidence-based Health Care (CEBHC). https://www.
cebhc.co.za/research-what-we-do/south-africa-grade-network/ (accessed 20 June 2023).
Garritty C, Gartlehner G, Nussbaumer-Streit B, et al. Cochrane Rapid Reviews Methods Group offers
evidence-informed guidance to conduct rapid reviews. J Clin Epidemiol 2021;130:13-22. https://doi.
org/10.1016/j.jclinepi.2020.10.007
Cochrane. Collaborating in response to COVID-19: Editorial and methods initiatives across Cochrane.
Cochrane Database Syst Rev 2020;12(Suppl 1):CD202002. https://doi.org/10.1002/14651858.CD202002
Tricco AC, Garritty CM, Boulos L, et al. Rapid review methods more challenging during COVID-19:
Commentary with a focus on 8 knowledge synthesis steps. J Clin Epidemiol 2020;126:177-183. https://
doi.org/10.1016/j.jclinepi.2020.06.029
Akl EA, Morgan RL, Rooney AA, et al. Developing trustworthy recommendations as part of an
urgent response (1 - 2 weeks): A GRADE concept paper. J Clin Epidemiol 2021;129:1-11. https://doi.
org/10.1016/j.jclinepi.2020.09.037
McCaul M, Tovey D, Young T, et al. Resources supporting trustworthy, rapid and equitable evidence
synthesis and guideline development: Results from the COVID-19 evidence network to support
decision-making (COVID-END). J Clin Epidemiol 2022;151:88-95. https://doi.org/10.1016/j.
jclinepi.2022.07.008
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised
studies of interventions. BMJ 2016;355:i4919. https://doi.org/10.1136/bmj.i4919
Sterne JAC, Savović J, Page MJ, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials.
BMJ 2019:l4898. https://doi.org/10.1136/bmj.l4898
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of
evidence and strength of recommendations. BMJ 2008;336(7650):924-926. https://doi.org/10.1136/
bmj.39489.470347.AD
Zhang D, Lai W, Liu X, Shen Y, Hong K. The safety of morphine in patients with acute heart failure:
A systematic review and meta-analysis. Clin Cardiol 2021;44(9):1216-1224. https://doi.org/10.1002/
clc.23691
Caspi O, Naami R, Halfin E, Aronson D. Adverse dose-dependent effects of morphine therapy in acute
heart failure. Int J Cardiol 2019;293:131-136. https://doi.org/10.1016/j.ijcard.2019.06.015
Dominguez-Rodriguez A, Avanzas P, Burillo-Putze G, Abreu-Gonzalez P. Influence of morphine
treatment on in-hospital mortality among patients with acute heart failure. Med Intensiva
;41(6):382-384. https://doi.org/10.1016/j.medin.2016.05.007
Gray A, Goodacre S, Seah M, Tilley S. Diuretic, opiate and nitrate use in severe acidotic acute
cardiogenic pulmonary oedema: Analysis from the 3CPO trial. QJM 2010;103(8):573-581. https://doi.
org/10.1093/qjmed/hcq077
Iakobishvili Z, Cohen E, Garty M, et al. Use of intravenous morphine for acute decompensated heart
failure in patients with and without acute coronary syndromes. Acute Card Care 2011;13(2):76-80.
https://doi.org/10.3109/17482941.2011.575165
Miró Ò, Gil V, Martín-Sánchez FJ, et al. Morphine use in the ED and outcomes of patients with
acute heart failure: A propensity score-matching analysis based on the EAHFE registry. Chest
;152(4):821-832. https://doi.org/10.1016/j.chest.2017.03.037
Sacchetti A, Ramoska E, Moakes ME, McDermott P, Moyer V. Effect of ED management on ICU use
in acute pulmonary edema. Am J Emerg Med 1999;17(6):571-574. https://doi.org/10.1016/s0735-
(99)90198-5
Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J. Noninvasive ventilation in acute
cardiogenic pulmonary edema. New Engl J Med 200810;359(2):142-151. https://doi.org/10.1056/
nejmoa0707992
Senoglu N, Oksuz H, Dogan Z, Yildiz H, Demirkiran H, Ekerbicer H. Sedation during noninvasive
mechanical ventilation with dexmedetomidine or midazolam: A randomized, double-blind, prospective
study. Curr Ther Res Clin Exp 2010;71(3):141-153. https://doi.org/10.1016/j.curtheres.2010.06.003
Longrois D, Conti G, Mantz J, Faltlhauser A, Aantaa R, Tonner P. Sedation in non-invasive
ventilation: Do we know what to do (and why)? Multidiscip Respir Med 2014;9(1):56. https://doi.
org/10.1186/2049-6958-9-56
Domínguez-Rodríguez A, Suero-Mendez C, Burillo-Putze G, et al. Midazolam versus morphine in
acute cardiogenic pulmonary oedema: Results of a multicentre, open-label, randomized controlled
trial. Eur J Heart Failure 2022;24(10):1953-1962. https://doi.org/10.1002/ejhf.2602
Krantz MJ, Palmer RB, Haigney MCP. Cardiovascular complications of opioid use. J Am Coll Cardiol
;77(2):205-223. https://doi.org/10.1016/j.jacc.2020.11.002
Behzadi M, Joukar S, Beik A. Opioids and cardiac arrhythmia: A literature review. Med Princ Pract
;27(5):401-414. https://doi.org/10.1159/000492616
Molina PE. Opioids and opiates: Analgesia with cardiovascular, haemodynamic and immune
implications in critical illness. J Int Med 2006;259(2):138-154. https://doi.org/10.1111/j.1365-
2005.01569.x
Duarte GS, Nunes-Ferreira A, Rodrigues FB, et al. Morphine in acute coronary syndrome:
Systematic review and meta-analysis. BMJ Open 2019;9(3):e025232. https://doi.org/10.1136/
bmjopen-2018-025232
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Clint Hendrikse, Vera Ngah, Idriss Kallon, Gustav Thom, Trudy D Leong, Karen Cohen, Michael McCaul
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
